Tags

Type your tag names separated by a space and hit enter

Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
J Neurochem. 2006 Sep; 98(6):1866-75.JN

Abstract

The present studies were done to investigate the effect of long-term nicotine treatment against nigrostriatal damage in non-human primates. Monkeys were administered nicotine in drinking water for 6 months to provide chronic but intermittent delivery as with smoking. Plasma nicotine levels ranged from 10 to 15 ng/mL, which were within the range in cigarette smokers. Animals were then lesioned with low doses of the dopaminergic neurotoxin MPTP for several months while nicotine was continued. The results showed that levels of striatal tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter, dopamine and nicotinic receptors were greater in nicotine-treated MPTP-lesioned primates than in lesioned animals not receiving nicotine. Nicotine had no effect in unlesioned animals. Monoamine oxidase activity was similar in unlesioned and lesioned animals treated with or without nicotine, suggesting that nicotine did not exert its effects through changes in MPTP or dopamine metabolism. MPTP-induced cell loss in the substantia nigra was unaffected by nicotine treatment, indicating that nicotine acts at the striatal level to restore/maintain dopaminergic function. These data further support the possibility that nicotine contributes to the lower incidence of Parkinson's disease in smokers.

Authors+Show Affiliations

The Parkinson's Institute, Sunnyvale, California, USA. mquik@parkinsonsinstitute.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16882311

Citation

Quik, Maryka, et al. "Chronic Oral Nicotine Treatment Protects Against Striatal Degeneration in MPTP-treated Primates." Journal of Neurochemistry, vol. 98, no. 6, 2006, pp. 1866-75.
Quik M, Parameswaran N, McCallum SE, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem. 2006;98(6):1866-75.
Quik, M., Parameswaran, N., McCallum, S. E., Bordia, T., Bao, S., McCormack, A., Kim, A., Tyndale, R. F., Langston, J. W., & Di Monte, D. A. (2006). Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Journal of Neurochemistry, 98(6), 1866-75.
Quik M, et al. Chronic Oral Nicotine Treatment Protects Against Striatal Degeneration in MPTP-treated Primates. J Neurochem. 2006;98(6):1866-75. PubMed PMID: 16882311.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. AU - Quik,Maryka, AU - Parameswaran,Neeraja, AU - McCallum,Sarah E, AU - Bordia,Tanuja, AU - Bao,Shanshan, AU - McCormack,Alison, AU - Kim,Amy, AU - Tyndale,Rachel F, AU - Langston,J William, AU - Di Monte,Donato A, Y1 - 2006/08/01/ PY - 2006/8/3/pubmed PY - 2006/11/9/medline PY - 2006/8/3/entrez SP - 1866 EP - 75 JF - Journal of neurochemistry JO - J Neurochem VL - 98 IS - 6 N2 - The present studies were done to investigate the effect of long-term nicotine treatment against nigrostriatal damage in non-human primates. Monkeys were administered nicotine in drinking water for 6 months to provide chronic but intermittent delivery as with smoking. Plasma nicotine levels ranged from 10 to 15 ng/mL, which were within the range in cigarette smokers. Animals were then lesioned with low doses of the dopaminergic neurotoxin MPTP for several months while nicotine was continued. The results showed that levels of striatal tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter, dopamine and nicotinic receptors were greater in nicotine-treated MPTP-lesioned primates than in lesioned animals not receiving nicotine. Nicotine had no effect in unlesioned animals. Monoamine oxidase activity was similar in unlesioned and lesioned animals treated with or without nicotine, suggesting that nicotine did not exert its effects through changes in MPTP or dopamine metabolism. MPTP-induced cell loss in the substantia nigra was unaffected by nicotine treatment, indicating that nicotine acts at the striatal level to restore/maintain dopaminergic function. These data further support the possibility that nicotine contributes to the lower incidence of Parkinson's disease in smokers. SN - 0022-3042 UR - https://www.unboundmedicine.com/medline/citation/16882311/Chronic_oral_nicotine_treatment_protects_against_striatal_degeneration_in_MPTP_treated_primates_ L2 - https://doi.org/10.1111/j.1471-4159.2006.04078.x DB - PRIME DP - Unbound Medicine ER -